Bristol-Myers Squibb (NYSE:BMY) has been very active in working to establish its leadership in the immuno-oncology arena, with Yervoy's near-blockbuster sales and strong growth last year ($960 million, up 36% year-over-year) a sign of the profits a pharma can derive from this exciting area of cancer treatment. Bristol's next big drug to watch in this area is nivolumab, but Bristol is clearly not interested in putting all of its eggs in one basket.

The company recently signed a deal potentially worth $1.2 billion with CytomX Therapeutics, involving up to four oncology targets using CytomX's Probody platform. In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson discuss the deal and its implications for Bristol's broader oncology pipeline.

David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.